Oxybutynin

Preview FDA label, AvPAK, oral, effective 2025-04-17. Full label on DailyMed

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using. Not yet reviewed by a ClinDose pharmacist.

Dosing in kidney impairment

Renal Impairment There were no studies conducted with Oxybutynin chloride extended-release tablets in patients with renal impairment.

Dosing in liver impairment

Hepatic Impairment There were no studies conducted with Oxybutynin chloride extended-release tablets in patients with hepatic impairment.